Compare · DFTX vs SGTX
DFTX vs SGTX
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Sigilon Therapeutics Inc. (SGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SGTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.88B, about 101.1x SGTX ($58.2M).
- DFTX has hit the wire 16 times in the past 4 weeks while SGTX has been quiet.
- SGTX has more recent analyst coverage (8 ratings vs 7 for DFTX).
- Company
- Definium Therapeutics Inc.
- Sigilon Therapeutics Inc.
- Price
- $43.77-2.23%
- $22.53-2.57%
- Market cap
- $5.88B
- $58.2M
- 1M return
- +4.30%
- -
- 1Y return
- +344.54%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 16
- 0
- Recent ratings
- 7
- 8
Sigilon Therapeutics Inc.
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Latest DFTX
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest SGTX
- SEC Form SC 13G/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 15-12G filed by Sigilon Therapeutics Inc.
- SEC Form EFFECT filed by Sigilon Therapeutics Inc.
- SEC Form 4 filed by Flagship Ventures Fund V General Partner Llc
- Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
- SEC Form SC 13D/A filed by Sigilon Therapeutics Inc. (Amendment)
- SEC Form 4: Eli Lilly & Co bought $25,639,916 worth of shares (1,718,493 units at $14.92)
- Lilly Completes Acquisition of Sigilon Therapeutics
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.
- SEC Form S-8 POS filed by Sigilon Therapeutics Inc.